New antibody shows promise against Post-Transplant virus
NCT ID NCT07261215
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tests a new drug called zuberitamab for people who develop Epstein-Barr virus (EBV) infection after a stem cell transplant. EBV can cause a serious condition called PTLD, which can be deadly if not treated. The drug targets a protein on infected cells to help clear the virus. About 20 adults who have had a stem cell transplant and have EBV in their blood will receive zuberitamab as their first treatment. The main goal is to see if the drug can clear the virus from the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.